Generation Bio Co.

As of September 30, 2025, Generation Bio Co. has 6.74M shares outstanding.

These figures are as of September 30, 2025. The price-to-sales ratio is 2.69, and the price-to-book ratio stands at -0.06.

As of September 30, 2025, Generation Bio Co. maintains a current ratio of 4.44, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2025. Return on assets (ROA) is negative at -33.79, reflecting losses generated across the asset base.

As of the close on February 10, 2026, Generation Bio Co.'s stock has declined approximately 23.71% over the past 52 weeks. The 50-day moving average sits at 5.49, while the 200-day moving average is 5.09.

Over the twelve months ended September 30, 2025, Generation Bio Co. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -589.59 and net profit margin of -410.13 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2025. Free cash flow yield is negative at -274.34: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.52, meaning Generation Bio Co. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Generation Bio Co.'s most recent stock split took place on July 22, 2025 with a 10:1 split ratio.

As of September 30, 2025, Generation Bio Co. has an Altman Z-Score of -9.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.